Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.65 |
| ▸ | ABL1 | P00519 | 2/20 | 0.60 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.60 |
| ▸ | BCR | P11274 | 2/20 | 0.60 |
| ▸ | ACHE | P22303 | 2/20 | 0.59 |
| ▸ | MAOB | P27338 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.57 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.57 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.57 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.57 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.57 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.57 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.57 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25873212 | 1.00 | ALKBH3 (0.65) | ALKBH3ABL1ABCB1BCRACHE | |
| SCHEMBL12871361 | 0.98 | ABL1 (0.63) | ALKBH3ABL1ABCB1BCRACHE | |
| SCHEMBL1180343 | 0.91 | ABL1 (0.69) | ALKBH3ABL1ABCB1BCRACHE | |
| SCHEMBL12770833 | 0.91 | ALKBH3 (0.57) | ALKBH3ABL1ABCB1BCRACHE | |
| SCHEMBL12871360 | 0.90 | ACHE (0.69) | ALKBH3ABL1ABCB1BCRACHE | |
| SCHEMBL12871359 | 0.88 | ABL1 (0.71) | ALKBH3ABL1ABCB1BCRACHE | |
| SCHEMBL13247865 | 0.87 | ABL1 (0.64) | ABL1ABCB1BCRMAOBCYP1A2 | |
| SCHEMBL1180412 | 0.87 | ABL1 (0.77) | ABL1ABCB1BCRMAOBCYP1A2 | |
| SCHEMBL792197 | 0.87 | ABL1 (0.77) | ABL1ABCB1BCRMAOBCYP1A2 | |
| SCHEMBL196765 | 0.87 | CYP3A4 (0.73) | ABL1ABCB1BCRACHEMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150376224-A1 | USE OF COMPOSITIONS OBTAINED BY CALCINING PARTICULAR METAL-ACCUMULATING PLANTS FOR IMPLEMENTING CATALYTICAL REACTIONS | UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES (FR) | 2015-12-31 | — | — | US | claimed |
| EP-2958670-A1 | USE OF COMPOSITIONS OBTAINED BY CALCINING PARTICULAR METAL-ACCUMULATING PLANTS FOR IMPLEMENTING CATALYTICAL REACTIONS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) | 2015-12-30 | — | — | EP | claimed |
| WO-2014128283-A1 | USE OF COMPOSITIONS OBTAINED BY CALCINING PARTICULAR METAL-ACCUMULATING PLANTS FOR IMPLEMENTING CATALYTICAL REACTIONS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2014-08-28 | — | — | WO | claimed |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ALTAVANT SCIENCES GMBH | 2023-09-19 | — | — | US | disclosed |
| WO-2022119756-A9 | COMPOSITIONS AND METHODS FOR INHIBITING M PRO PROTEASE ACTIVITY AND FOR PREVENTING AND TREATING SARS-COV-2 INFECTION | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023004240-A1 | MACROCYLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-26 | — | — | WO | disclosed |
| WO-2022119756-A1 | COMPOSITIONS AND METHODS FOR INHIBITING M PRO PROTEASE ACTIVITY AND FOR PREVENTING AND TREATING SARS-COV-2 INFECTION | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2022-06-09 | — | — | WO | disclosed |
| US-11254597-B2 | Method for the production of a material of plant origin that is rich in phenolic acids, comprising at least one metal, for carrying out organic synthesis reactions | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-02-22 | — | — | US | disclosed |
| US-20200390778-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. | 2020-12-17 | — | — | US | disclosed |
| EP-3674303-A1 | NOVEL TRYPTOPHAN HYDROXYLASE INHIBITOR AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | Gwangju Institute of Science and Technology (KR) | 2020-07-01 | — | — | EP | disclosed |
| WO-2020047487-A1 | METHODS FOR TREATING CANCER WITH RORGAMMA INHIBITORS AND STATINS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-03-05 | — | — | WO | disclosed |
| WO-2003007954-A2 | SULFONYL ARYL HYDROXAMATES AND THEIR USE AS MATRIX METALLOPROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-01-30 | — | — | WO | disclosed |
| EP-1279656-A2 | Process for preparing unsymmetrical biaryls and alkylated aromatic compounds from arylnitriles | DSM N.V. (NL) | 2003-01-29 | — | — | EP | disclosed |
| US-6441177-B1 | Tertiary amines | HOFFMANN-LA ROCHE INC. | 2002-08-27 | — | — | US | disclosed |
| EP-0778264-B1 | Tertiary amines having antimycotic and cholesterol lowering activity | HOFFMANN LA ROCHE (CH) | 2001-07-11 | — | — | EP | disclosed |
| US-6034275-A | FUGICIDES; ATICHOLESTEROL AGENTS | HOFFMANN-LA ROCHE INC. (US) | 2000-03-07 | — | — | US | disclosed |
| EP-0766559-A4 | CANNABINOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1997-08-06 | — | — | EP | disclosed |
| EP-0778264-A1 | Tertiary amines having antimycotic and cholesterol lowering activity | F. HOFFMANN-LA ROCHE AG (CH) | 1997-06-11 | — | — | EP | disclosed |
| EP-0766559-A1 | CANNABINOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-04-09 | — | — | EP | disclosed |
| WO-1996002248-A1 | CANNABINOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390778-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | XDH, PNPO, LOX | ALKBH3 1626/4885ABL1 3986/4885ABCB1 2152/4885 |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | ALKBH3 730/4885ABL1 1529/4885ABCB1 1038/4885 |
| US-20150376224-A1 | USE OF COMPOSITIONS OBTAINED BY CALCINING PARTICULAR METAL-ACCUMULATING PLANTS FOR IMPLEMENTING CATALYTICAL REACTIONS | CACYBP, PPA1, IPMK | ALKBH3 1430/4885ABL1 2909/4885ABCB1 2706/4885 |
| US-11254597-B2 | Method for the production of a material of plant origin that is rich in phenolic acids, comprising at least one metal, for carrying out organic synthesis reactions | COMT, VARS1, CROCC | ALKBH3 2374/4885ABL1 2558/4885ABCB1 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.